MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MVX-220, an investigational adeno-associated virus (AAV) gene therapy for the treatment of AS.
MavriX Bio will host a webinar in the coming months to provide additional details regarding the clinical trial design, eligibility criteria, and expected timelines.